SK+F Oncology

What SK+F Oncology does

SK+F Oncology is the oncology division of Eskayef Pharmaceuticals Limited, part of Bangladesh-based Transcom Group. The division manufactures and distributes 43+ generic anticancer pharmaceuticals, spanning chemotherapy, targeted therapy, and immunotherapy modalities, serving oncology patients, hospitals, and prescribing oncologists in Bangladesh and select international markets.

The division operates a state-of-the-art, OEL-validated manufacturing facility in Narayanganj, built with technical collaboration from Telstar, a Europe-based life science solutions provider. The facility employs isolator technology and containment systems required for cytotoxic handling, and is compliant with US FDA, UK MHRA, EU EMA, and WHO GMP standards — making it the first and only oncology facility of this caliber in Bangladesh. Distribution is conducted through 31 patient service points across Bangladesh, with international market reach leveraging the facility's multi-jurisdictional regulatory clearances.

The business model is sales-led and direct, with the division engaging hospitals, oncologists, and patients through its own distribution network rather than relying on third-party pharma distributors. The division is led by Simeen Rahman and operates with a 82-person team, drawing on the 30+ year brand reputation of parent Eskayef Pharmaceuticals. The unit is private, with no external funding rounds disclosed.

Name

SK+F Oncology

Legal name

Eskayef Pharmaceuticals Limited

Website

https://skf-oncology.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

51–100 employees

Short description

SK+F Oncology is the oncology division of Eskayef Pharmaceuticals (Bangladesh), manufacturing and distributing 43+ generic anticancer drugs via an OEL-validated facility and 31 patient service points across Bangladesh, with select international reach.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIACAA

Oncology Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIABAL

Generic Hospital & Institutional Products

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

Keywords

• Oncology pharmaceutical manufacturing
• Generic anticancer drugs
• Cytotoxic drug production
• Chemotherapy medications
• Cancer treatment pharmaceuticals

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Anticancer Pharmaceutical Products: Sale of branded generic anticancer medications including injectables, tablets, and capsules for various cancer types. Revenue generated through direct sales to healthcare facilities and patients.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

SK+F Oncology manufactures and distributes branded generic anticancer pharmaceutical products in multiple dosage forms including tablets, capsules, liquid injections, lyophilized injections, and prefilled syringes. The company's portfolio covers chemotherapy agents, targeted therapies, immunotherapy drugs, and supportive care medications for treating breast, lung, colon, ovarian, head and neck, liver, kidney, brain, blood, and stomach cancers. Products are distributed through 31 patient service points across Bangladesh, direct hospital supply, and international export channels.

Product overview

SK+F Oncology (Eskayef Oncology) is a pharmaceutical division of Eskayef Pharmaceuticals Limited, Bangladesh, focused on manufacturing and distributing generic anticancer medicines. The product portfolio consists of 43+ generic oncology drugs across multiple therapeutic categories including chemotherapy agents (taxanes, platinum compounds, antimetabolites, alkylating agents, vinca alkaloids), targeted therapies (tyrosine kinase inhibitors, PARP inhibitors, multi-kinase inhibitors), immunotherapy drugs (PD-1/PD-L1 inhibitors, anti-HER2 antibodies, anti-CD20 antibodies), and supportive care medications. The portfolio covers treatment for various cancers including breast, lung, colon, ovarian, head & neck, liver, kidney, brain, blood, and stomach cancers. Manufacturing utilizes advanced isolator technology for both solid dosage forms (tablets, capsules) and injectable forms (liquid and lyophilized injections, prefilled syringes). The company operates state-of-the-art OEL-validated facilities compliant with FDA, MHRA, EMA, WHO GMP standards.

Differentiator

Problem solved

Functional benefit

Products and services

• Abeclib (Abemaciclib) Kinase inhibitor for oncology treatment. 150mg and 200mg tablet formulations.
• Atemab (Atezolizumab) Monoclonal antibody immunotherapy. Solution/concentrate for intravenous infusion. 60mg/mL strength.
• Bigatab (Brigatinib) Kinase inhibitor indicated for ALK-positive metastatic non-small cell lung cancer. 90mg tablets.
• Bleoma (Bleomycin Sulfate) Antitumor antibiotic. Lyophilized powder for injection. 15 Units/vial.
• Bemab (Bevacizumab) Anti-VEGF monoclonal antibody. Injection solution. 100mg/4mL strength.
• Capcitab (Capecitabine) Antimetabolite chemotherapy agent. Film-coated tablet in 150mg and 500mg strengths. Used for breast, colon, and gastric cancers.
• Carbotor (Carboplatin) Platinum-based chemotherapy. Liquid injection in 150mg and 450mg strengths.
• Cistor (Cisplatin) Platinum-based chemotherapy agent. Lyophilized powder for injection in 10mg and 50mg strengths.
• Cycloph (Cyclophosphamide) Alkylating agent. Liquid multidose vial for injection. 1g/5mL and 200mg/mL strengths. Also used for nephrotic syndrome.
• Cytosor (Cytarabine) Antimetabolite chemotherapy. Injection solution. 100mg/1mL and 500mg/1mL strengths.
• Damid (Darolutamide) Androgen receptor inhibitor. Oral tablet. 300mg strength. Indicated for non-metastatic castration-resistant prostate cancer.
• Dasatab (Dasatinib) Tyrosine kinase inhibitor. Film-coated tablets. 20mg and 100mg strengths.
• Degaris (Degarelix) GnRH receptor antagonist. Subcutaneous injection. 80mg and 120mg strengths.
• Docetor (Docetaxel) Taxane chemotherapy agent. Injection concentrate. 20mg/1mL and 80mg/4mL strengths.
• Doxotor (Doxorubicin Hydrochloride) Anthracycline chemotherapy. Lyophilized powder for injection. 10mg and 50mg vial strengths. Indicated for acute leukemias, Wilms' tumor.
• Enerplat (Eltrombopag) Thrombopoietin receptor agonist. Tablet. 7's pack. Indicated for immune thrombocytopenia.
• Etopor (Etoposide) Topoisomerase inhibitor chemotherapy. Lyophilized powder for injection. 100mg strength.
• Exemis (Exemestane) Aromatase inhibitor. 25mg tablets. 30 tablets per pack. Adjuvant treatment for postmenopausal women with ER-positive early breast cancer.
• Fenitab (Sorafenib Tosylate) Multi-kinase inhibitor. Film-coated tablet. 200mg strength. Used for liver and kidney cancers.
• Filgram (Filgrastim) Granulocyte colony-stimulating factor. Pre-filled syringe. 30MU/0.5mL strength.
• Flurotor (Fluorouracil) Antimetabolite chemotherapy. Injection solution. 250mg/5mL and 500mg/5mL strengths.
• Folimax (Calcium Folinate) Folinic acid injection. 100mg/10mL strength. Used as rescue therapy with methotrexate and in 5-FU regimens.
• Fulvest (Fulvestrant) Estrogen receptor antagonist. Intramuscular injection. 250mg/5mL strength. For HR+ HER2- postmenopausal women.
• Gemtor (Gemcitabine Hydrochloride) Nucleoside analog chemotherapy. Injection. 200mg and 1g vial strengths. Indicated for ovarian, breast, lung, and pancreatic cancers.
• Ibrutab (Ibrutinib) Bruton's tyrosine kinase inhibitor. 140mg capsules. 28's pack.
• Ican (Irinotecan) Topoisomerase I inhibitor chemotherapy. Injection. 40mg/2mL strength.
• Imitab (Imatinib Mesylate) Tyrosine kinase inhibitor. Film-coated tablets. 100mg and 400mg strengths. Used for CML and GIST.
• Lurbin (Lurbinectedin) Alkylating agent. Lyophilized powder for injection. 4mg strength.
• Meganor (Megestrol Acetate) Synthetic progestin. 160mg tablets. Used for breast cancer and appetite stimulation.
• Nab Paclitor (Nanoparticle Albumin-bound Paclitaxel) Taxane chemotherapy with albumin-bound formulation. Lyophilized powder for injectable suspension. Indicated for metastatic breast cancer.
• Nimab (Nivolumab) PD-1 immune checkpoint inhibitor. Solution concentrate for IV infusion. 40mg/4mL and 100mg/10mL strengths.
• Olatab (Olaparib) PARP inhibitor. 100mg tablets. 30's pack. For ovarian and breast cancers with BRCA mutations.
• Osimatab (Osimertinib) EGFR tyrosine kinase inhibitor. Film-coated tablets. 40mg and 80mg strengths. For NSCLC with T790M mutation.
• Oxator (Oxaliplatin) Platinum-based chemotherapy. Lyophilized powder for injection. 50mg and 100mg vial strengths.
• Paclitor (Paclitaxel) Taxane chemotherapy. Liquid injection. 30mg/5mL, 100mg/16.7mL, and 300mg/50mL strengths. Indicated for ovarian, breast, and lung cancers.
• Pazotab (Pazopanib) Multi-tyrosine kinase inhibitor. Film-coated tablet. 200mg. Capsule-shaped, white, film-coated. 28's pack.
• Pemab (Pembrolizumab) PD-1 checkpoint inhibitor. Solution for IV infusion. 100mg/4mL (25mg/mL).
• Pemetor (Pemetrexed) Antimetabolite chemotherapy. Lyophilized powder for injection. 100mg and 500mg vial strengths. Indicated for NSCLC and mesothelioma.
• R-Lix (Relugolix) GnRH receptor antagonist. Oral tablet. 120mg. 30's pack.
• Regotab (Regorafenib) Multi-kinase inhibitor. Film-coated tablets. 40mg. 28's pack. Used for colorectal cancer and GIST.
• Rubitor (Rituximab) Anti-CD20 monoclonal antibody. Lyophilized powder for injection. 10mg and 50mg vial strengths.
• Trumab (Trastuzumab) Anti-HER2 monoclonal antibody. Lyophilized powder for injection. 440mg strength.
• VCR (Vincristine) Vinca alkaloid chemotherapy. Liquid injection. 2mg/2mL. Requires refrigeration. Indicated for acute leukemia.
• Vinbas (Vinblastine) Vinca alkaloid chemotherapy. Injection. 10mg/10mL. Requires refrigeration. Indicated for Hodgkin's lymphoma.

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• TelstarcoreTechnology or Integration · 1 January 2018Technical collaboration with Telstar, a Europe-based global leader in providing life science solutions, for the development of SK+F Oncology's state-of-the-art manufacturing facility. Telstar provided expertise in isolator technology and pharmaceutical manufacturing equipment including tablet presses, granulation suites, and coating systems.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Regional players

• Renata Limited: Bangladesh-listed pharmaceutical company with animal health, generics and specialty exposure. Comparable as a domestically scaled Bangladesh pharma competitor.
• Incepta Pharmaceuticals: Bangladesh-based generic manufacturer with strong injectables and oncology presence. Comparable as a domestic specialty/generic competitor targeting similar hospital channels in Bangladesh.
• Square Pharmaceuticals: Top-tier Bangladesh pharmaceutical company with diversified branded generics including oncology and biologics. Comparable in scale and regulatory ambition within the same Bangladesh operating environment.
• Beximco Pharmaceuticals: Largest pharmaceutical exporter from Bangladesh with a broad generics portfolio including oncology. Comparable Bangladesh-headquartered manufacturer competing in the same domestic and emerging-market generics channels.

Broad incumbents

• Cipla: Indian-headquartered global pharmaceutical major with strong oncology and emerging-market presence. Comparable on generic oncology manufacturing and emerging-market distribution model.
• Teva Pharmaceutical Industries: Global leader in generic oncology injectables and oral solids with FDA/EMA approvals. Comparable as a broad incumbent competing in the same generic oncology molecules.

Emerging players

• Biocon: India-based biopharmaceutical company with leading biosimilars portfolio including trastuzumab and other mAbs. Comparable on the biosimilars/mAb manufacturing dimension of SK+F's portfolio.
• Dr. Reddy's Laboratories: Indian multinational with significant generic oncology and biosimilars franchise, exporting globally. Comparable as a generic/biosimilar oncology manufacturer with international ambitions.

Direct peers

• Beacon Pharmaceuticals: Bangladesh-based pharmaceutical manufacturer with a focused oncology and specialty injectable portfolio. Most direct domestic competitor to SK+F Oncology's generic oncology and cytotoxic injectable offering.
• Natco Pharma: India-based specialty generic manufacturer with a meaningful oncology portfolio including cytotoxics and targeted therapies. Closest analogue in business model and therapeutic focus.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/skfoncology

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SK+F Oncology